Let's check the charts of SLB to see if all that bearish news has been discounted.
Omeros Corp. and EyePoint Pharmaceuticals each have promising treatments that could send their shares skyward.
The tech sector has been the victim of the recent "on again, off again" rotation. That may really just mean that the group has been victimized by its own success.
Small-caps have outperformed, which helped to produce improved breadth and better stock picking, and the action is no longer being driven by trade headlines.
Sabre made heavy investments this year that crimped net profit margins, but that should pay off handsomely starting in 2020.
After seeing the idea raised -- and derided -- I found that the Dow has been over 27,000 twice this year and each time it did this....
Without danger of major macro news and with earnings landing, investors focus on merits of individual stocks once again.
I have the answer behind the conundrum that forces stocks up that should be going lower.
As the robotics sector of medicine begins to mature, ISRG finds itself as one of the old guard.
Biden's proposed doubling of the capital gains tax rate and the seemingly anti-business stance of his opponents are likely to drag the market down.